Program Information
Tumor Response Based On Radiomics During the Course of Proton Therapy for Stage III NSCLC
R Zhang1,2*, B Jiang1,2 , X Wang1 , X Zhang1 (1) The University of Texas MD Anderson Cancer Center, Houston, Texas (2) Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Presentations
SU-I-GPD-J-108 (Sunday, July 30, 2017) 3:00 PM - 6:00 PM Room: Exhibit Hall
Purpose: The purpose of this study is to use radiomics feature change during the course of proton therapy to study the tumor response.
Methods: 10 patients treated using passive proton therapy (PSPT) were selected. Each patient underwent a 7-week proton therapy and had a weekly 4D CT to monitor the tumor and anatomical changes during the treatment. The primary GTV was drawn by the physician on T50 (end of exhale phase) CT and weekly T50 CT. The IBEX software was used to calculate the 689 Radioman features of GTV. The feature during each week was compared with that of week 0 or week 1. The number of features showing significant change during each week was used to study which week the tumor shows significant response.
Results: Comparison of features between 1 and week 2, 3, 4,5,6,7, there is no significant changes for any features at week 2, 3, 4, and 606 out of 689 features showed significant changes at week 5, 6 and 7. Among all features, the Grey Level Nonuniformity feature shows most significant changes. Using week 0 as the baseline features, there are some feature changes at week 3 and 4 but majority feature changes happened at week 5 and after similar to that observed using week 1 as the baseline.
Conclusion: CT Radiomics feature changes is a significant biomarker to reflect the tumor change during the course of PSPT. The 5th week of PSPT shows the most significant response of the primary tumor during the course of PSPT.
Contact Email: